Navigation Links
InterMune Reports Second Quarter 2009 Financial Results and Business Highlights
Date:8/6/2009

enses

    -- R&D expense:  anticipated to be in a range of approximately $90 to
       $100 million, net of development cost reimbursements under the Roche
       collaboration.  Of this amount, approximately 60 percent is
       attributed to pirfenidone which includes expenses for CAPACITY, RECAP,
       the preparation and support of NDA and MAA submissions and
       manufacturing.

       Approximately 35 percent of the R&D expense is attributed to the
       company's one-third share of all development expenses incurred by the
       collaboration with Roche on ITMN-191.  The balance of 2009 R&D expense
       is related to the advancement of a named pirfenidone analog compound,
       ITMN-520, toward an expected IND filing in mid-2010.

    -- G&A expense: anticipated to be in a range of approximately $35 to $40
       million.  The G&A guidance range includes approximately $5.0 million of
       various pirfenidone pre-launch costs.

Conference Call and Webcast Details

InterMune will host a conference call today at 4:30 p.m. EDT to discuss its financial results for its second quarter and first six months of 2009, its forward-looking financial guidance and its clinical development programs. Interested investors and others may participate in the conference call by dialing 888-799-0528 (U.S.) or 973-200-3372 (international), conference ID# 22196018. A replay of the webcast and teleconference will be available approximately three hours after the call.

To access the webcast, please log on to the company's website at www.intermune.com at least 15 minutes prior to the start of the call to ensure adequate time for any software downloads that may be required.

The teleconference replay will be available approximately three hours after the call. The teleconference replay will be available for 10 business days following
'/>"/>

SOURCE InterMune, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. InterMune to Release Second Quarter Financial Results on August 6
2. InterMune to Present at Goldman Sachs Healthcare Conference
3. InterMune Reports First Quarter 2009 Financial Results and Business Highlights
4. InterMune to Release First Quarter Financial Results on April 30
5. InterMune and Pharmasset to Discuss INFORM-1 Results From EASL Conference, April 25
6. InterMune to Present at Canaccord Adams Hepatitis C Conference
7. InterMune to Present at Citis 4th Annual Biotech Day
8. InterMune to Present Abstracts on HCV Protease Inhibitor ITMN-191 and HCV Development Program at the EASL Meeting
9. InterMune Reports Fourth Quarter and Full Year 2008 Financial Results and Business Highlights
10. InterMune to Release Fourth Quarter, Full Year 2008 Financial Results on February 26
11. InterMune Announces Issuance of U.S. Patent for ITMN-191
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 2013 was a banner year ... Technologies®. They saw continued independent research led by the ... awarded a $1 million grant from the Susanne Marcus ... Behavior” a peer reviewed journal, Amy Grant highlighted Brainwave ...
(Date:1/15/2014)... Jan. 15, 2014 TaiGen Biotechnology Company, Limited ("TaiGen") ... with R-Pharm, a leading Russian pharmaceutical company, to develop ... Russian Federation , Turkey ... (CIS). Nemonoxacin is a novel antibiotic for the treatment of ...
(Date:1/14/2014)... January 14, 2014 Histogen, Inc., a ... of cells grown under simulated embryonic conditions, today announced ... with Suneva Medical, Inc. for physician-dispensed aesthetic products containing ... , This agreement is an amendment to the existing ...
(Date:1/14/2014)... NY (PRWEB) January 14, 2014 EquitiesIQ, ... Alliqua, Inc. (OTCQB: ALQA). Alliqua is an emerging biomedical ... serve the wound care market. , Free report download: ... restructured with a seasoned management team and Board, which ...
Breaking Biology Technology:Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 2Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3
... elected mayor of Colorados largest city, businessman John Hickenlooper invited ... was to ceremoniously bury the hatchet of intra-regional rivalry and ... metropolitan area, or not at all. , ,Every suburban ... a near-unanimous effort to pass a $4.7-billion mass transit initiative ...
... data quality firm Firstlogic for about $69 million ... second quarter. , ,Firstlogic is a privately held firm that ... sure their data is as correct as they need to ... call centers, web sites, customer relationship management systems, and business ...
... settled with a Belgian company that sued last September ... virus genotyping technology from Innogenetics, for undisclosed financial terms. ... Aril 2004 Third Wave forged a deal under which ... line of products in Europe. It was Third Wave's ...
Cached Biology Technology:Economic collaboration in Denver sets tall goal for Wisconsin 2Economic collaboration in Denver sets tall goal for Wisconsin 3
(Date:4/23/2014)... using triclosan as an antimicrobial ingredient in soaps, toothpastes ... are reporting new evidence that appears to support these ... Chemical Research in Toxicology , found that triclosan, as ... growth of human breast cancer cells in lab dishes ... and colleagues note that hormonal imbalances seem to play ...
(Date:4/23/2014)... of the family of bacteria that causes whooping ... reveals surprising findings about the bacteria,s origin and ... strategies to control this respiratory disease, which kills ... of 343 strains of the Bordetella pertussis ... the last 100 years illustrates how vaccination has ...
(Date:4/23/2014)... HOUSTON, April 23, 2014 A biomedical engineer at ... highly innovative technology to make blood transfusions safer. His ... the National Institutes of Health (NIH). , Blood ... one of modern medicine,s absolute necessities. Without them, for ... mean transfusions are perfect, however. There,s strong evidence that ...
Breaking Biology News(10 mins):In lab tests, the antimicrobial ingredient triclosan spurs growth of breast cancer cells 2Impact of whooping cough vaccination revealed 2UH biomedical engineer works to make blood transfusions safer 2UH biomedical engineer works to make blood transfusions safer 3
... a single dose of chemotherapy alongside radiotherapy could improve ... long-term side-effects, a new study reports.,As many as 96% ... ten years from diagnosis (1), but more advanced forms ... can have serious long-term complications.,Researchers at The Institute of ...
... terrorists targeted the United States with an anthrax attack, health ... such as knowing the likelihood of an individual becoming infected, ... how long to give antibiotics to protect people from ... letters killed five people and infected 17 others in the ...
... and herbs, especially Mexican oregano, all contain apigenin and ... the lab by inhibiting an important enzyme, according to ... induced cell death in two aggressive human pancreatic cancer ... we pre-treated cancer cells with apigenin for 24 hours, ...
Cached Biology News:Chemotherapy before radiotherapy for testicular cancer could reduce long-term side-effects 2Answering crucial questions about anthrax exposure 2Answering crucial questions about anthrax exposure 3Answering crucial questions about anthrax exposure 4Celery, artichokes contain flavonoids that kill human pancreatic cancer cells 2
RABBIT ANTI ISOCITRATE DEHYDROGENASE...
... two highly efficient methods of identifying recombinant ... By using the large-scale screen method in ... is to transfer partial colonies of E. ... into the solutions provided by the kits ...
Recombinant Rat Leptin, CF...
Rat whole blood (Sprague-Dawley, averaging 7-8 weeks of age, either sex) is collected at the time of slaughter and refrigerated within 6 hours, and processed and frozen within 24 hours. The serum is ...
Biology Products: